Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)

Inclusion Criteria

• •SCREENING
• •1. Any patient regardless of age or sex, with diagnosis of either:
• •* EBV positive Hodgkin's lymphoma
• •* EBV Positive non-Hodgkin's Lymphoma (regardless of histologic subtype)
• •* EBV (associated)-T/NK-lymphoproliferative disease
• •* Severe Chronic Active EBV (CAEBV) -- CAEBV is defined as patients with high EBV viral load in plasma or PBMC (\>4000 genomes per ug PBMC DNA) and/or biopsy tissue positive for EBV
• •* Other EBV positive malignancies (e.g. nasopharyngeal carcinoma, smooth muscle tumors, etc.)
• •AND
• •* in first or subsequent relapse (Group A)
• •* with active disease persisting despite therapy (Group B)
• •* with active disease if immunosuppressive chemotherapy is contraindicated e.g. patients who develop Hodgkin disease after solid organ transplantation or if the lymphoma is a second malignancy e.g. a Richter's transformation of CLL. (Group C)
• •2. EBV positive tumor
• •3. Weighs at least 12kg
• •4. Informed consent (and assent as applicable) obtained from patient/guardian.
• •TREATMENT
• •1. Any patient regardless of age or sex, with diagnosis of either:
• •* EBV positive Hodgkin's lymphoma
• •* EBV Positive non-Hodgkin's Lymphoma (regardless of histologic subtype)
• •* EBV (associated)-T/NK-lymphoproliferative disease
• •* Severe Chronic Active EBV (CAEBV) -- CAEBV is defined as patients with high EBV viral load in plasma or PBMC (\>4000 genomes per ug PBMC DNA) and/or biopsy tissue positive for EBV
• •* Other EBV positive malignancies (e.g. nasopharyngeal carcinoma, smooth muscle tumors, etc.)
• •AND
• •* in first or subsequent relapse (Group A)
• •* with active disease persist despite therapy (Group B)
• •* with active disease if immunosuppressive chemotherapy is contraindicated e.g. patients who develop Hodgkin disease after solid organ transplantation or if the lymphoma is a second malignancy e.g. a Richter's transformation of CLL. (Group C)
• •2. EBV positive tumor
• •3. Patients with life expectancy greater than or equal to 6 weeks
• •4. Patients with bilirubin less than or equal to 3x upper limit of normal
• •5. AST less than or equal to 5x upper limit of normal
• •6. Hemoglobin greater than or equal to 7.0 (may be a transfused value)
• •7. Patients with a creatinine less than or equal to 2x upper limit of normal for age
• •8. Pulse oximetry of \> 90% on room air
• •9. Patients should have been off other investigational therapy for 30 days prior to infusion.
• •10. Patients with a Karnofsky/Lansky score of more than or equal to 50.
• •11. Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom.
• •12. Informed consent (and assent as applicable) obtained from patient/guardian.